Best Stocks To Invest In

HanesBrands (NYSE: HBI  ) has entered into a definitive agreement to acquire Maidenform Brands (NYSE: MFB  ) , Hanes and Maidenform� announced today.

Hanes is to pay $23.50 per share in cash, a 30% premium over the last 30 days' average closing price. The enterprise value of the transaction, according to Hanes, is approximately $575 million.

Hanes expects the synergies produced by combining the two intimate apparel companies to approach full value within three years and provide more than $500 million more in annual sales, and earnings per share of $0.60.

Hanes said the combination of Maidenform's bra business and Hanes' panty business will presents long-term growth opportunities. The deal would add brands like Maidenform, Flexees, and Self Expressions to the HanesBrands roster that includes Playtex, Bali, Champion, Wonderbra, and its namesake Hanes. HanesBrands anticipates being able to potentially lower the costs of Maidenform products for retailers and consumers. Currently Maidenform sources its products from third-party manufacturers. With the acquisition, HanesBrands said Maidenform will now be able to take advantage of HanesBrands' company-owned manufacturing, which is supplemented by third-party manufacturers.

Top Cheap Stocks To Invest In Right Now: Trovagene Inc (TROV)

TrovaGene, Inc. (TrovaGene), incorporated on April 26, 2002, is a development-stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. The Company's novel tests predominantly use transrenal DNA (Tr-DNA) and transrenal RNA (Tr-RNA). The Company's technology is used to all transrenal nucleic acids (Tr-NA). The Company�� urine-based test addresses market needs, such as women�� healthcare-fetal medicine-down syndrome, infectious diseases, cancer testing, transplantation, drug development and monitoring of therapeutic outcomes, ultra-sensitive analytical and detection system, technologies for the collection, shipment and storage of urine specimens, and transrenal nucleic acid extraction, and instrumentation/system platform.

On January 18, 2011, the Company entered into an asset purchase agreement pursuant to which the Company acquired a hybridoma able to produce a monoclonal antibody targeting the NPM1 biomarker. On February 8, 2011, the Company entered into a sublicense agreement with MLL Munchner Leukamielabor (MLL). In July, 2011, the Company entered into a sublicense agreement with Fairview Health Services (Fairview) for NPM1 patent rights.

In October 2011, the Company entered into a license agreement pursuant to which the Company licensed the patent rights to a specific gene mutation with respect to chronic lymphoblastic leukemia. On December 12, 2011, the Company entered into a license agreement pursuant to which the Company licensed the patent rights to hairy cell leukemia biomarkers. On February 1, 2012, the Company acquired the clinical laboratory improvement amendments (CLIA) laboratory assets of MultiGEN Diagnostics, Inc. (MultiGEN).

Advisors' Opinion:

• [By Daniel Lauchheimer]

  In the past few weeks, I wrote two articles about TrovaGene (TROV) -- one detailing the history of the DNA market generally and the molecular diagnostics -- and TROV's place therein -- market specifically, and the second detailing the company's internal valuation. In this article, I will value TROV on an external, relative basis. Specifically, I will compare TROV to another molecular diagnostics company, Exact Sciences (EXAS), and try to show that while the market seems to have given EXAS a fair shake, it has not done the same for TROV. I will prove this argument by looking at both companies' addressable markets, and their respective progress at bringing the products to market. However, before we take this deep dive into both companies, I will take a moment to review each of the companies' products, so we have a strong background before turning to the deeper analysis.

Best Stocks To Invest In: Neuralstem Inc (CUR)

Neuralstem, Inc., incorporated in 1997, is a development-stage company focused on the development and commercialization of treatments for central nervous system disease based on transplanting human neural stems cells and the use of small molecule drugs. The Company has developed and maintains a portfolio of patents and patent applications that form base for its research and development efforts in the area of neural stem cell research. The Company's focus is the development of methods to generate replacement cells from neural stem cells.

In October of 2011, the Company announced that after reviewing safety data from the first 12 patients, the FDA granted approval for the trial to advance to transplanting patients in the cervical (upper back) region for the last six patients in the trial. As of December 31, 2011, the Company had treated 14 patients. In February of 2011, the Company commenced a Phase Ia clinical trial of its drug compound, NSI-189, which is being developed for the treatment of depressive disorder and other psychiatric indications. In October of 2011, the Company completed the Phase Ia portion of the trial. In December of 2011, the Company received approval from the FDA to commence the Phase Ib portion of the trial.

During the year ended December 31, 2011, the Company was selected as the primary subcontractor for the United States Department of Defense (DOD) contract to develop human neural stem cell technology for the treatment of cancerous brain tumors. The Company commenced work on the project in May 2011. The Company has developed and patented a series of small molecule compounds (low molecular weights organic compounds which can efficiently cross the blood/brain barrier).

Advisors' Opinion:

• [By James E. Brumley]

  Nine times out of ten, I'd be hesitant to be bullish on a stock that's already made a 57% run up in just five months. Neuralstem, Inc. (NYSEMKT:CUR) is that one out of ten instances though, where there's plenty more room ahead to keep on running. In fact, I think CUR could almost double in value from where it is now before the rally effort ran out of gas.

Best Stocks To Invest In: Physicians Formula Holdings Inc.(FACE)

Physicians Formula Holdings, Inc. develops, markets, and sells cosmetic and skin care products for the mass market channel. Its cosmetic products include face powders, bronzers, concealers, blushes, foundations, eye shadows, eyeliners, mascaras, and brow makeup; and skin care products comprise cleansers, moisturizers, and treatments. Physicians Formula Holdings, Inc. sells its products to various retailers in the food retail, drug chain, mass volume, specialty retail, and wholesale channels in the United States, Canada, Australia, South Africa, Turkey, Mexico, El Salvador, and Panama. The company, formerly known as PFI Holdings Corp., was founded in 2003 and is based in Azusa, California.

Advisors' Opinion:

• [By CRWE]

  Physicians Formula Holdings, Inc. (Nasdaq:FACE) reported that it has received an unsolicited, nonbinding proposal to acquire all its outstanding shares of common stock at a price of $4.90 per share, subject to several conditions, including the completion of due diligence and securing of financing commitments by the third party who submitted the proposal and the negotiation of a mutually acceptable definitive agreement

Best Stocks To Invest In: Tetra Technologies Inc.(TTI)

TETRA Technologies, Inc. operates as a diversified oil and gas services company. The company operates in three divisions: Fluids, Production Enhancement, and Offshore. The Fluids Division manufactures and markets clear brine fluids, additives, and other associated products and services to the oil and gas industry for use in well drilling, completion, and workover operations in the United States, as well as in various countries in Latin America, Europe, Asia, the Middle East, and Africa; and markets liquid and dry calcium chloride products to non-energy markets. The Production Enhancement division offers production testing services in various oil and gas basins in the United States, as well as in Mexico, Brazil, northern Africa, and the Middle East; and wellhead compression-based production enhancement services in the onshore producing regions of the United States, as well as various onshore basins in Canada, Mexico, South America, Europe, and Asia. The Offshore division pr ovides offshore services, including downhole and subsea oil and gas services, such as well plugging and abandonment, and wireline services; decommissioning and construction services utilizing heavy lift barges and various technologies for offshore oil and gas production platforms and pipelines; and conventional and saturated air diving services. It also engages in the exploration, development, and production of oil and gas properties in the offshore and onshore U.S. Gulf Coast region. This division provides its services to oil and gas companies and independent operators. The company was founded in 1981 and is headquartered in the Woodlands, Texas.

Advisors' Opinion:

• [By Monica Wolfe]

  Tetra Technologies (TTI)

  During the second quarter Ashton upped his stake in Tetra Technologies by 91.82%. The guru purchased 71,800 shares in the second quarter price range of $8.29 to $11.21, with an estimated average price of $9.74. Since his buy the price per share has increased approximately 20.1%.

• [By Ben Levisohn]

  What a ride it’s been for investors in�Tetra Technologies (TTI) today.

  Agence France-Presse/Getty Images

  Shares of Tetra Technologies traded down as much as 16% this morning after the oil & gas services company reported a profit of 6 cents not including Maritech and other unusual items, missing analyst forecasts for 19 cents. Tetra Technologies also said it would make between 50 cents and 60 cents during fiscal 2014, below forecasts for 66 cents.

  At 2:38 p.m., however, Tetra was trading down just 0.8% at $10.88. RBC’s Kurt Hallead and team explain why:

  Tetra Technologies rallied after starting the day at -15%. We think there was an overreaction to the headline miss and�Tetra Technologies’ core operating business results, along with 2H14 guidance, were in line with expectations. Moving forward, the company has some key catalysts on the horizon that should lead to significantly improved operating performance and investor awareness. Key Catalysts:

  1. Get Maritech (E&P P&A liability in GoM) off the books. Ideally by 3Q. Once this is done,�Tetra Technologies may implement a dividend or share repo program.

  2. Broaden Production Testing customer base, which should lead to a ramp in margins.

  3. Increase scale of Compressco through M&A, along with awareness of the MLP’s value to Tetra Technologies.

  4. Sell the offshore services business to simplify business structure.

  Shares of Tetra Technologies are down 12% in 2014.

• [By Seth Jayson]

  When judging a company's prospects, how quickly it turns cash outflows into cash inflows can be just as important as how much profit it's booking in the accounting fantasy world we call "earnings." This is one of the first metrics I check when I'm hunting for the market's best stocks. Today, we'll see how it applies to TETRA Technologies (NYSE: TTI  ) .

Best Stocks To Invest In: Dell Inc.(DELL)

Dell Inc. provides integrated technology solutions in the information technology (IT) industry worldwide. It designs, develops, manufactures, markets, sells, and supports mobility and desktop products, including notebooks, workstations, tablets, smartphones, and desktop PCs, as well as servers and networking products. The company offers storage solutions, including storage area networks, network-attached storage, direct-attached storage, and various backup systems. It also provides IT and business services comprising transactional services, such as support, managed deployment, enterprise installation, and configuration services; outsourcing services, including data center and systems management, network management, life cycle application development and management, and business process outsourcing services; and project-based services consisting of IT infrastructure, applications, business process, and business consulting services. In addition, the company offers third-part y software products comprising operating systems, business and office applications, anti-virus and related security software, and entertainment software; and peripheral products, such as printers, televisions, notebook accessories, mouse, keyboards, networking and wireless products, and digital cameras. Further, it provides financial services, including originating, collecting, and servicing customer receivables related to the purchase of its products and third-party technology products. The company sells its products and services directly through its sales representatives, telephone-based sales, and online sales; and through retailers, third-party solution providers, system integrators, and third-party resellers. It serves corporate businesses, law enforcement agencies, small and medium businesses, consumers, and public institutions that include government, education, and healthcare organizations. Dell Inc. was founded in 1984 and is headquartered in Round Rock, Texas.

Advisors' Opinion:

• [By Travis Hoium]

  On a company level, investors should follow the never-ending saga of Dell's (NASDAQ: DELL  ) potential buyout. The company has already spurned Carl Icahn, and now Michael Dell himself is under pressure to increase his contribution if he wants to make a deal happen. Private-equity firm Silver Lake Partners has balked at adding to the pot in an effort to close the deal. One reason is that the PC market has deteriorated further since Dell brought up buyout plans -- and the company was unappealing enough as it was, even at that discounted price. Dell will certainly be the talk of Wall Street today.

• [By Sean Williams]

  Also in the news...
  In this week's episode of "Dells� (NASDAQ: DELL  ) of Our Lives," we received word that the company's board of directors approved an $0.08 quarterly cash distribution, payable on July 22, 2013 for shareholders on record as of July 1, 2013. Sure, this news is a bit more tame than the mudslinging Carl Icahn and Dell's management have thrown back and forth at each other over the past couple of weeks, but we should know more within the next five weeks, when Dell shareholders vote on the proposed offer of $13.65 per share by founder Michael Dell and private-equity firm Silver Lake Partners.

• [By Chris Neiger]

  NVIDIA said the Quadro K6000 GPU will be�available this coming fall from Dell (NASDAQ: DELL  ) , HP (NYSE: HPQ  ) , Lenovo, and other major workstation providers.

Best Stocks To Invest In: Credit Suisse Group AG (CSGN)

Credit Suisse Group AG is a Switzerland-based holding company engaged in private banking, investment banking and asset management areas. It operates through four divisions: Private Banking, which consists of the Wealth Management Clients and Corporate & Institutional Clients business; Investment Banking, provides a range of financial products and services, with a focus on client-driven, flow-based and capital-efficient businesses; Asset Management, offers a range of asset class products, including alternative investments, and multi-asset class solutions, including equities and fixed income products, and Shared Services, which provides centralized corporate services and business support for the Company's divisions. Advisors' Opinion:

• [By Ruth David]

  Credit Suisse Group AG (CSGN) and Numis Securities Ltd. managed the sale, along with Canaccord Genuity Ltd. Rothschild acted as financial adviser.

• [By Inyoung Hwang]

  Credit Suisse (CSGN)�� Chen took a new look at publicly listed private-equity firms, including Apollo Global Management LLC, Blackstone Group LP (BX) and Carlyle Group LP. (CG) Investors are still struggling to properly value them, he says.